MONDAY INVESTOR DEADLINE: Erasca, Inc. (NASDAQ: ERAS) investors with substantial losses have opportunity to lead shareholder Class Action lawsuit, Robbins Geller Rudman & Dowd LLP announces. * 59 mins ago SAN DIEGO, Aug. 07, 2026 (GLOBE NEWSWIRE) - Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Erasca, Inc. (NASDAQ: ERAS) common stock between January 14, 2025 and April 26, 2026, inclusive (the "Class Period"), have until this upcoming Monday, August 10, 2026 to seek appointment as lead plaintiff of the Erasca class action lawsuit. Captioned Cheng v. Erasca, Inc., No. 26-cv-03481 (S.D. Cal.), the Erasca class action lawsuit charges Erasca as well as certain of Erasca's executive officers with violations of the Securities Exchange Act of 1934. Shailene Woodley reveals how she celebrated her Emmy nomination If you suffered substantial losses and wish to serve as lead plaintiff of the Erasca class action lawsuit, please provide your information here: You can also contact attorneys Ken Dolitsky or Michael Albert of Robbins Geller by calling 800/851-7783 or via e-mail at [email protected]. CASE ALLEGATIONS: Erasca is a clinical-stage precision oncology company that focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Erasca's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors. The Erasca class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) ERAS-0015's preclinical data was based on improper comparisons to Revolution Medicines, Inc. and placed Erasca at risk of violating patent and trade secret protections; and (ii) based on the foregoing, the defendants lacked a reasonable basis for their positive statements related to ERAS-0015. On April 27, 2026, before the market opened, Erasca allegedly disclosed that it received a letter from Revolution Medicines, Inc. asserting that Erasca's ERAS-0015 infringes on a Revolution Medicines, Inc. patent and is connected to alleged trade secret misappropriation. On this news, the price of Erasca stock fell nearly 11%, according to the complaint. The Erasca class action lawsuit further alleges that after market close on April 27, 2026, Erasca reported preliminary Phase I clinical data for ERAS-0015 and disclosed that one patient who received 24 mg of ERAS-0015 had died approximately one month after starting ERAS-0015. Erasca allegedly further disclosed that comparisons between ERAS-0015 and other product candidates were based on cross-study analyses and "not based on any head-to-head clinical trials," and that such comparisons are "inherently limited and such data may not be directly comparable." On this news, the price of Erasca stock declined more than 48%, according to the complaint. THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired Erasca common stock during the Class Period to seek appointment as lead plaintiff in the Erasca class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Erasca class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Erasca class action lawsuit. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Erasca class action lawsuit. ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud and shareholder rights litigation. Its Firm ranked #1 on the most recent ISS Securities Class Action Services Top 50 Report, recovering more than $916 million for investors in 2025. This marks its fourth #1 ranking in the past five years. And in those five years alone, Robbins Geller recovered $8.4 billion for investors - $3.4 billion more than any other law firm. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever - $7.2 billion - in In re Enron Corp. Sec. Litig. Please visit the following page for more information: Past results do not guarantee future outcomes. Services may be performed by attorneys in any of its offices. Robbins Geller Rudman & Dowd LLP Ken Dolitsky Michael Albert 655 W. Broadway, Suite 1900, San Diego, CA 92101 800/851-7783

ERAS AUGUST 10, 2026 DEADLINE: Erasca, Inc. investors have opportunity to lead shareholder class action lawsuit - HBSS. Jul 31, 2026, 14:41 ET SAN FRANCISCO, July 31, 2026 /PRNewswire/ - Hagens Berman, a national shareholder rights firm, is actively investigating claims in a class action alleging securities law violations at Erasca, Inc. (NASDAQ: ERAS). The litigation alleges Erasca and its senior executives misled investors by providing a false narrative regarding the competitive advantage, safety profile, and intellectual property (IP) moat surrounding its lead oncology candidate, ERAS-0015. Hagens Berman urges Erasca investors who suffered significant losses to contact the firm now to discuss their rights. Class Period: Jan. 14, 2025 - Apr. 26, 2026 Lead Plaintiff Deadline: Aug. 10, 2026 Visit: www.hbsslaw.com/investor-fraud/eras Contact the Firm Now: [email protected] 844-916-0895 The Alleged Erasca (ERAS) Securities Fraud: Erasca's public disclosures throughout the class period (January 14, 2025 - April 26, 2026) repeatedly championed ERAS-0015 as a "best-in-class" pan-RAS molecular glue. The complaint alleges the company intentionally obfuscated critical risks by: * Improper Preclinical Comparisons: Allegedly using flawed cross-study analyses to claim superiority over competing therapies, such as Revolution Medicines' RMC-6236, without a reasonable basis. * Concealing IP Disputes: Assuring investors that its IP was secure while allegedly failing to disclose that its practices exposed the company to significant patent infringement and trade secret misappropriation claims from Revolution Medicines. * Downplaying Safety Risks: Touting favorable safety results while allegedly failing to adequately disclose the risks associated with ERAS-0015 clinical trials, which later surfaced following a patient death. The Truth Emerges: The complaint alleges on April 27-28, 2026, the artificial inflation in Erasca's stock price was removed following two major disclosures: * Patent Infringement Allegations: The company disclosed a legal challenge from Revolution Medicines regarding patent infringement and trade secret misappropriation. * Adverse Clinical Data: Erasca reported preliminary data including a patient death linked to the ERAS-0015 trial. These disclosures triggered a sharp stock decline, with shares falling significantly and wiping out over $2.8 billion in market capitalization. Hagens Berman's Investigation "We're investigating whether Erasca may have intentionally misled investors about ERAS-0015's safety profile and about a potential moat in its particular, highly competitive cancer treatment space," said Reed Kathrein, the Hagens Berman partner leading the firm's investigation. Investor Rights and Lead Plaintiff Deadline Investors who purchased or acquired Erasca common stock between January 14, 2025, and April 26, 2026, may be eligible to serve as the lead plaintiff in the ongoing litigation. The court-imposed deadline to move for appointment as lead plaintiff is August 10, 2026. If you invested in Erasca and have substantial losses, or have knowledge that may assist the firm's investigation, submit your losses now" If you'd like more information and answers to other frequently asked questions about the Erasca case and the firm's investigation, read more" Whistleblowers: Persons with non-public information regarding Erasca should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected]. About Hagens Berman Hagens Berman is a global plaintiffs' rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman's team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw. Attorney Advertising. Prior results do not guarantee a similar outcome in any future case. SOURCE Hagens Berman Sobol Shapiro LLP

Erasca faces class action allegations as deadline nears. Erasca investors confront potential fraud implications. Sit tight, folks, because this one's a doozy. Hagens Berman, the notorious shareholder rights firm, has thrown the hammer down on Erasca, Inc. (NASDAQ: ERAS). The class action alleges some pretty dicey moves with Erasca's main oncology contender, ERAS-0015, and from what it smells like to me, there might be some serious puffery going on. Allegations that could turn into pandora's box. The legal tussle kicks up a stink about how Erasca (let's call it ERAS to save time) potentially pulled the wool over investor eyes. They've been promoting ERAS-0015 as the next big thing in oncology. 'Best-in-class,' they said - as per the not-so-flattering complaint. Meanwhile, there's a claim they were playing dangerous hide-and-seek with safety risks, dangling superiority without a leg to stand on. Throw in an alleged disregard for patent troubles, and it's looking like a real penny dreadful. "Erasca's been accused of misleading investors about ERAS-0015's safety and about holding some mighty flimsy cards when it came to its IP moat." - Reed Kathrein, Hagens Berman The fallout so far. Let's zoom in on the result once these claims hit the fan back in April 2026. When the truth started sliding out, ERAS's stock took the mother of all nose-dives. Shareholders saw over $2.8 billion in market value evaporate faster than a small-town rumor. Two critical revelations were the nails in the coffin: the company confronted patent infringement allegations from Revolution Medicines, and to top it off with a messy bow, preliminary safety data wasn't just poor - it reported a patient's death. It sounds bleak, and believe me, the market took notice. * Patent Battles Brewing: Revolution Medicines has allegedly now ganged up on ERAS with some legitimate gripes on IP infringement and trade secrets. * Safety Conflagration: Bad news on clinical trials surfaced - unfortunately, patient mortality isn't easy to sweep under any rug. Investor action required now. Now, here's the kicker - investors within this shipwreck's timeframe, from January 2025 through April 2026, have a shot to become the lead plaintiff. They've got until August 10, 2026, before this window slams shut. If you threw your hard-earned into Erasca stock and watched it crumple, this is your chance to at least get your voice heard in court. Don't sleep on this, reach out to Hagens Berman and put yourself out there. Oh, and if you happen to have a morsel of inside intel, the SEC's Whistleblower Program might have some interest and perhaps a pretty penny for your efforts - 30 percent of any SEC recovery, not chump change. Looking ahead: time to gut check your portfolio. This soap opera with Erasca should be a red flag for any investor out there. If you're not questioning what's in your portfolio after this, maybe it's time to - especially in the biotech world. Transparency, honesty of data, and corporate accountability aren't just nice buzzwords; they're bedrock principles. The market's a battlefield, and getting blindsided by allegations like these can batter anyone's positions. Watch your portfolios, stay smart, and always ask the difficult questions - before the hard lessons come your way. Frank truth, from years of bruises and wins alike. Keep ahead of the curve and don't become another tally mark in legal documents.